Equities research analysts forecast that Bruker (NASDAQ:BRKR) will announce $0.24 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Bruker’s earnings, with estimates ranging from $0.19 to $0.26. Bruker reported earnings of $0.19 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 26.3%. The company is expected to report its next earnings results on Wednesday, May 2nd.
According to Zacks, analysts expect that Bruker will report full-year earnings of $1.37 per share for the current year, with EPS estimates ranging from $1.36 to $1.41. For the next year, analysts anticipate that the firm will report earnings of $1.53 per share, with EPS estimates ranging from $1.48 to $1.58. Zacks’ EPS averages are an average based on a survey of analysts that follow Bruker.
Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, February 8th. The medical research company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.02. The firm had revenue of $530.50 million during the quarter, compared to analysts’ expectations of $506.74 million. Bruker had a return on equity of 26.68% and a net margin of 4.45%. The firm’s quarterly revenue was up 12.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.46 EPS.
BRKR has been the subject of a number of recent research reports. Zacks Investment Research cut Bruker from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. Cowen reiterated a “hold” rating and set a $35.00 price objective on shares of Bruker in a research report on Thursday, December 21st. BidaskClub cut Bruker from a “buy” rating to a “hold” rating in a research report on Saturday, February 10th. Evercore ISI initiated coverage on Bruker in a research report on Wednesday, January 3rd. They set an “in-line” rating and a $36.00 price objective for the company. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective on shares of Bruker in a research report on Thursday, December 14th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $32.62.
Bruker stock traded up $0.24 during midday trading on Monday, reaching $29.36. 658,461 shares of the company were exchanged, compared to its average volume of 562,992. The stock has a market cap of $4,542.91, a PE ratio of 24.45, a P/E/G ratio of 1.93 and a beta of 1.12. Bruker has a 1 year low of $21.83 and a 1 year high of $36.53. The company has a current ratio of 2.59, a quick ratio of 1.66 and a debt-to-equity ratio of 0.57.
The firm also recently declared a quarterly dividend, which was paid on Friday, March 23rd. Shareholders of record on Tuesday, March 6th were paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date of this dividend was Monday, March 5th. Bruker’s payout ratio is 13.22%.
A number of large investors have recently modified their holdings of the business. Swiss National Bank lifted its stake in shares of Bruker by 1.6% in the 4th quarter. Swiss National Bank now owns 188,800 shares of the medical research company’s stock valued at $6,480,000 after purchasing an additional 2,900 shares in the last quarter. Fuller & Thaler Asset Management Inc. lifted its stake in shares of Bruker by 39.9% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 271,240 shares of the medical research company’s stock valued at $9,309,000 after purchasing an additional 77,400 shares in the last quarter. California Public Employees Retirement System lifted its stake in shares of Bruker by 8.9% in the 4th quarter. California Public Employees Retirement System now owns 270,363 shares of the medical research company’s stock valued at $9,279,000 after purchasing an additional 22,147 shares in the last quarter. Quadrature Capital Ltd acquired a new position in shares of Bruker in the 4th quarter valued at about $642,000. Finally, Invictus RG lifted its stake in shares of Bruker by 18.6% in the 4th quarter. Invictus RG now owns 10,398 shares of the medical research company’s stock valued at $357,000 after purchasing an additional 1,634 shares in the last quarter. 65.27% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “$0.24 Earnings Per Share Expected for Bruker (BRKR) This Quarter” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/04/09/0-24-earnings-per-share-expected-for-bruker-brkr-this-quarter.html.
Bruker Company Profile
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.
Get a free copy of the Zacks research report on Bruker (BRKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.